Surgical Science Sweden

Surgical And Robotic Simulation Will Improve Patient Safety

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

16 Jan 25

Updated

29 Nov 25

Views

69

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-80.2%

7D

-6.1%

Loading

1Y

-80.2%

7D

-6.1%

You can edit this narrative until Nov 30 1:10 AM. Then, changes will post as Updates.

Author's Valuation

SEK 77.659.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 29 Nov 25

Fair value Decreased 48%

SUS: Analyst And Investor Day Updates Will Support Sector Leadership Prospects

Analysts have significantly lowered their price target for Surgical Science Sweden from SEK 149 to SEK 77.60, citing reduced growth and profit margin forecasts as key factors behind the adjustment. What's in the News Surgical Science Sweden held an Analyst/Investor Day and provided key updates to analysts and investors (Key Developments).

Shared on 15 Nov 25

Fair value Decreased 8.59%

SUS: Strong Revenue Momentum Will Likely Support Future Sector Leadership

Analysts have reduced their price target for Surgical Science Sweden, lowering it from SEK 163 to SEK 149. They cite slightly higher discount rates and adjusted expectations around profit margins, despite stronger projected revenue growth.

Shared on 05 Sep 25

With both the discount rate and future P/E ratio essentially unchanged, Surgical Science Sweden's fair value remains steady at SEK163.00. Valuation Changes Summary of Valuation Changes for Surgical Science Sweden The Consensus Analyst Price Target remained effectively unchanged, at SEK163.00.

Shared on 01 May 25

Fair value Decreased 23%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 15%

AnalystConsensusTarget has increased future PE multiple from 23.7x to 27.6x.

Shared on 26 Mar 25

Fair value Decreased 6.80%

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 1.79%

AnalystConsensusTarget has decreased profit margin from 29.9% to 24.0% and increased future PE multiple from 24.4x to 29.9x.

AnalystConsensusTarget Fair Value

SEK 77.6

59.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

9.70%

Medical Equipment revenue growth rate

7.21%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

5.73%

Calculation

SEK 244.17m

Earnings '28

x

19.17x

PE Ratio '28

=

SEK 4.68b

Market Cap '28

SEK 4.68b

Market Cap '28

/

51.03m

No. shares '28

=

SEK 91.71

Share Price '28

SEK 91.71 Share Price '28

Discounted to 2025 @ 5.74% p.a.

=

SEK 77.56

Fair Value '25